SUNNYVALE, Calif., March 20, 2015 /PRNewswire/ -- Users of Elekta's MOSAIQ® OIS version 2.61 can now ePrescribe controlled substances using the same workflow they employ for all other MOSAIQ ePrescriptions. With the new MOSAIQ functionality – Electronic Prescribing of Controlled Substances (EPCS) – users can eliminate the time-consuming practice of signing and faxing paper forms to the pharmacy when controlled substances are prescribed.
"The hallmark of MOSAIQ product development has been the continuous drive to increase functionality," says Todd Powell, Executive Vice President, Elekta Software. "The ability to ePrescribe controlled substances in MOSAIQ is not only more convenient for physicians, but increases patient safety through interaction checking and improved legibility of controlled drug prescriptions. We expect that soon all U.S. states will require ePrescribing of controlled substances, so we made sure our customers could stay ahead of these mandates."
In addition to EPCS capabilities, Elekta will help MOSAIQ users meet U.S. federal identity proofing requirements as they apply to providers. All scripts for controlled substances are validated in accordance with DEA Regulations, including dual-factor authentication requirements, before they are electronically delivered to the pharmacy.
"As required, Elekta has completed a certification process with a third-party auditor to enable EPCS to be integrated in the MOSAIQ workflow," Powell adds. "Our MOSAIQ customers have been asking for this functionality for some time to help streamline their ePrescribing workflow. We listened to them and now can provide it to them."
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: firstname.lastname@example.org
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1 770-670-2524, e-mail: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.